Anti-Leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-Targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBF2AT3::GLIS2 AML

Introduction: CBFA2T3::GLIS2 (CBF-GLIS) is an oncogenic fusion associated with a lethal and highly refractory childhood myeloid leukemia manifested by the RAM phenotype, uniquely expressed in infants and young children. Conventional chemotherapy and stem cell transplant (SCT) result in extraordinari...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2023-11, Vol.142 (Supplement 1), p.4295-4295
Main Authors: Williams, Robin, Miller, Lane, Massaro, Stephanie, Krieger, Elizabeth, Pauly, Melinda, Nelson, Catherine, Johnson, Rebecca, Welch, Jennifer J.G., Bhojwani, Deepa, Moghimi, Babak, Neff, Philip, Horton, Terzah M., Imran, Hamayun, Ribeiro, Raul C., Guinipero, Terri L., Kutny, Matthew A., Bautista, Felipe, Johnson, Amy, Lewing, Karen, Gamis, Alan S, Brackett, Julienne, McCall, David, Bhatla, Teena, Sulis, Maria Luisa, Tellinghuisen, Amy, Beck, Jill C., Meshinchi, Soheil
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction: CBFA2T3::GLIS2 (CBF-GLIS) is an oncogenic fusion associated with a lethal and highly refractory childhood myeloid leukemia manifested by the RAM phenotype, uniquely expressed in infants and young children. Conventional chemotherapy and stem cell transplant (SCT) result in extraordinarily high rates of induction failure (>80%) and near uniform fatality with 2-year survival
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2023-180141